Abstract
Background
The incidence of malignant melanoma (MM) is steadily rising, with only a minor increase in mortality. At present, there is no consensus regarding recommendations for follow-up programmes for MM, and health care programmes currently involve different schedules. With increasing opportunities to administer successful treatment for early disseminated disease, it may be of interest to engage MM patients and/or relatives in self-control.
Objectives
The aim of the present study was to analyse both the time to, and the location of, the first metastatic lesion in order to provide help for the patient, relatives, and health professionals, and ensure better follow-up.
Materials and methods
Data from the Swedish Melanoma Register, pathology registers, and the Cause of Death Register were used. Patients from the south-east region diagnosed with primary cutaneous MM between 1993 and 2007 were selected and data were correlated to characteristics of the primary tumour.
Results
Metastases developed in 421 of the 2,910 patients with primary cutaneous MM in Stage I and II of the disease. Thirty-five percent of all recurrences were detected during the first year. Time to first metastasis to the skin and lymph nodes was almost identical.
Conclusion
The vast majority of the recurrences were diagnosed at sites that were easily recognised by the patient and relatives; self-examination may therefore be a worthwhile approach. Our findings further indicate that the follow-up programme should focus on the first three years after diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–86.
Leiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 2012; 66: 37–45.
Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One 2012; 7: e32955.
Eriksson H, Lyth J, Mansson-Brahme E, et al. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden. Eur J Cancer 2013; 49: 2705–16.
Eriksson H, Lyth J, Mansson-Brahme E, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. J Clin Oncol 2014; 32: 1356–64.
Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013; 20: 3961–8.
Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20: vi51–8.
Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163: 238–56.
Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270–83.
Regionalt Cancercenrum Sydöst. Vårdprogram för malignt melanom. Available at: http://www.cancercentrum.se/Global/RCC%20Samverkan/Dokument/V%C3%A5rdprogram/NatVP_Malignt_melanom_130520_final%5Bl%C3%A5ng%5D.pdf.
Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011; 65: 1032–47.
New Zealand Guideline group. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand; 2008. Available at: http://www.cancer.org.au/content/pdf/ HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines- ManagementofMelanoma.pdf.
Leiter U, Marghoob AA, Lasithiotakis K, et al. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res 2009; 19: 50–7.
Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999; 38: 549–57.
Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62–70.
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–206.
Joosse A, De Vries E, van Eijck CH, Eggermont AM, Nijsten T, Coebergh JW. Reactive oxygen species and melanoma: an explanation for gender differences in survival? Pigment Cell Melanoma Res 2010; 23: 352–64.
Shen S, Wolfe R, McLean CA, Haskett M, Kelly JW. Characteristics and associations of high-mitotic-rate melanoma. JAMA Dermatol 2014; 150: 1048–55.
Savoia P, Fava P, Nardo T, Osella-Abate S, Quaglino P, Bernengo MG. Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res 2009; 19: 321–6.
Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14: 1924–33.
Cromwell KD, Ross MI, Xing Y, et al. Variability in melanoma posttreatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 2012; 22: 376–85.
Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995; 221: 9–71, 566-9;discussion.
Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16: 941–7.
Eriksson H, Frohm-Nilsson M, Jaras J, et al. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. Br J Dermatol 2015; 172: 175–86.
Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140: 249–54.
Hajdarevic S, Schmitt-Egenolf M, Sundbom E, Isaksson U, Hornsten A. Coping styles in decision-making among men and women diagnosed with malignant melanoma. J Health Psychol 2013; 18: 1445–55.
Morton RL, Rychetnik L, McCaffery K, Thompson JF, Irwig L. Patients’ perspectives of long-term follow-up for localised cutaneous melanoma. Eur J Surg Oncol 2013; 39: 297–303.
Kittler H, Weitzdorfer R, Pehamberger H, Wolff K, Binder M. Compliance with follow-up and prognosis among patients with thin melanomas. Eur J Cancer 2001; 37: 1504–9.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–19.
Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade:new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19: 5300–9.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Maroti, M., Ulff, E., Lyth, J. et al. A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence. Eur J Dermatol 26, 586–591 (2016). https://doi.org/10.1684/ejd.2016.2845
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2016.2845